SecBot SecBot
8-K ·Filed Aug 6, 2026

COLL

COLLEGIUM PHARMACEUTICAL, INC
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001628280-26-053849
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong non-GAAP EPS beat suggests improving profitability, but the guidance cut signals near-term pressure from the pain portfolio and AG Nucynta pricing. Traders should watch the back-to-school ADHD season for JORNAY PM and AZSTARYS ramp, and monitor pain portfolio trends in Q3 earnings for confirmation of stabilization or further erosion.

DirectionMixed
Confidencehigh
Horizonweeks

Nucynta ER

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already on the market — approved since 2008 (IR) and 2011 (ER)
Next catalyst
None dated

What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$29.11
T+0 close · Aug 6, 2026 · via day close
Latest settled
−18.24%
T+60 · $23.80
Vs SPY
−16.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $29.11entry
  2. T+1 · 3mo ago +1.24%α +0.63% · $29.47
  3. T+5 · 3mo ago −3.30%α −4.51% · $28.15
  4. T+20 · 3mo ago −18.58%α −19.18% · $23.70
  5. T+60 · 18d ago −18.24%α −16.57% · $23.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M (+6% YoY). However, the company lowered full-year 2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M), citing weaker-than-expected authorized generic Nucynta pricing. The GAAP net loss of ($15.1M) reflects acquisition-related costs from the recently closed AZSTARYS deal. The ADHD portfolio (JORNAY PM +41% YoY, AZSTARYS $12.9M partial quarter) is strong, but the pain portfolio declined 9% YoY, creating a mixed outlook.

Key Financial Metrics

EPS
$1.92
est $1.48 · +29.7%
Revenue
$199.9M
+6.3% YoY
Rating
beat
Guidance
$825M-$855M
lowered

Key Facts

  • Q2 2026 adjusted EPS $1.92 vs consensus $1.48, beat 29.7%
  • Q2 2026 revenue $199.9M, +6% YoY
  • GAAP net loss ($15.1M) due to acquisition-related expenses and amortization
  • Completed AZSTARYS acquisition in May; added $12.9M in partial quarter revenue
  • Lowered FY2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M)
  • JORNAY PM net revenue grew 41% YoY to $46.1M; pain portfolio fell 9% to $140.9M
  • Cash from operations $71.3M; cash and marketable securities $129.5M at quarter end

Financial Impact

Adjusted EPS beat by $0.44 vs consensus; full-year guidance cut by ~$40M on both product revenue and adjusted EBITDA

revenueadjusted EBITDAadjusted EPSGAAP net income

Risk Factors

  • Continued decline in pain portfolio (Belbuca, Xtampza ER, Nucynta franchise)
  • Lower-than-expected AG Nucynta pricing impacting full-year EBITDA
  • Integration risk and debt load from the AZSTARYS acquisition (term notes payable $852.8M)
  • Potential share dilution from convertible notes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-053849
Document: collq22026earningspresen.htm0001628280-26-053849
Document: coll-20260806.htm0001628280-26-053849
Document: 0001628280-26-053849-index-headers.html0001628280-26-053849
Document: 0001628280-26-053849-index.html0001628280-26-053849
Document: 0001628280-26-053849.txt0001628280-26-053849
8-K Data (Synthetic)0001628280-26-053849

Track record

24 reports on COLL

Performance horizon

1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
  2. Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
  4. Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  6. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
  8. Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  9. Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  10. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026